Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor

European Journal of Dermatology

Volumn 25, Issue 2, 2015, Pages 177-180

  Galliker, Nadja A ^a   Murer, Carla ^a   Kamarashev, Jivko ^a   Dummer, Reinhard ^a   Goldinger, Simone M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adverse event; BRAF inhibition; MEK inhibition; Melanoma; Panniculitis; Targeted therapy

Indexed keywords

B RAF KINASE INHIBITOR; BETAMETHASONE VALERATE; BINIMETINIB; DABRAFENIB; ENCORAFENIB; MEFENAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PREDNISONE; TRAMETINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BENZIMIDAZOLE DERIVATIVE; BRAF PROTEIN, HUMAN; CARBAMIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CASE REPORT; CELL INFILTRATION; DRUG INDUCED DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTATIC MELANOMA; MIDDLE AGED; PANNICULITIS; SKIN NODULE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; GENETICS; MELANOMA; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CARBAMATES; HUMANS; IMIDAZOLES; MALE; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; OXIMES; PANNICULITIS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84931346333     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2014.2512     Document Type: Article

References (30)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 94954.
2. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
3. Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst 2014; 106: djt435.
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
5. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
6. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
7. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 10714.
8. Larkin J, Ascierto PA, Dréno B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med 2014; 371: 1867-76.
9. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med 2014; 371: 1877-88.
10. Robert C, Karaszewska B, Schachter J, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2014 Nov 16. [Epub ahead of print].
11. Holderfield M, Nagel TE, Stuart DD. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer 2014; 111: 640-5.
12. Sun C, Wang L, Huang S, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014; 508: 118-22.
13. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009; 106: 20411-6.
14. Villanueva J, Infante JR, Krepler C, et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 2013; 4: 1090-9.
15. Sibaud V, Lamant L, Maisongrosse V, Delord JP. [Adverse skin reactions induced by BRAF inhibitors: a systematic review]. Ann Dermatol Venereol 2013; 140: 510-20.
16. Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987-94.
17. Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314-22.
18. Schad K, Baumann Conzett K, Zipser MC, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16: 1058-64.
19. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
20. Anforth R, Liu M, Nguyen B, et al. Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 2014; 55: 250-4.
21. Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148: 357-61.
22. Monfort JB, Pagès C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 22: 399-401.
23. Novoa RA, Honda K, Koon HB, Gerstenblith MR. Vasculitis and panniculitis associated with vemurafenib. J Am Acad Dermatol 2012; 67: e271-2.
24. Villani AP, Zaharia D, Dalle S, Depaepe L, Balme B, Thomas L. Vemurafenib-induced panniculitis. Eur J Dermatol 2013; 23: 258-60.
25. Sinha R, Edmonds K, Newton-Bishop J, Gore M, Larkin J, Fearfield L. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol 2013; 31: e320-1.
26. Kim GH, Levy A, Compoginis G. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol 2013; 40: 667-9.
27. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, CotoSegura P, Vazquez-Lopez F, Perez-Oliva N. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity. Dermatol Online J 2013; 19: 16.
28. Chaminade A, Conte H, Jouary T, et al. BRAF inhibitorsinduced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis. J Eur Acad Dermatol Venereol 2015; 29: 392-3.
29. Choy B, Chou S, Anforth R, Fernández-Peñas P. Panniculitis in Patients Treated With BRAF Inhibitors: A Case Series. Am J Dermatopathol 2014; 36: 493-7.
30. Dummer R, Tsao H, Robert C. How cutaneous eruptions help to understand the mode of action of kinase inhibitors. Br J Dermatol 2012; 167: 965-7.